Analysts predict that Trillium Therapeutics Inc (NASDAQ:TRIL) (TSE:TR) will report ($0.42) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Trillium Therapeutics’ earnings. The highest EPS estimate is ($0.40) and the lowest is ($0.43). Trillium Therapeutics reported earnings of ($0.51) per share in the same quarter last year, which indicates a positive year over year growth rate of 17.6%. The company is scheduled to announce its next quarterly earnings report on Friday, May 10th.

On average, analysts expect that Trillium Therapeutics will report full-year earnings of ($1.90) per share for the current fiscal year, with EPS estimates ranging from ($2.43) to ($1.67). For the next fiscal year, analysts expect that the company will post earnings of ($1.21) per share, with EPS estimates ranging from ($1.61) to ($0.74). Zacks’ EPS calculations are an average based on a survey of research analysts that cover Trillium Therapeutics.

Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) last posted its quarterly earnings data on Monday, March 11th. The biotechnology company reported ($0.42) EPS for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.24.

A number of analysts recently commented on TRIL shares. ValuEngine cut Trillium Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, December 25th. HC Wainwright reduced their price objective on Trillium Therapeutics from $10.00 to $4.00 and set a “buy” rating for the company in a research report on Wednesday, March 13th.

Trillium Therapeutics stock opened at $0.60 on Friday. The firm has a market cap of $8.85 million, a P/E ratio of -0.26 and a beta of 2.29. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.56 and a quick ratio of 3.56. Trillium Therapeutics has a one year low of $0.51 and a one year high of $7.50.

Institutional investors and hedge funds have recently modified their holdings of the business. Two Sigma Investments LP purchased a new stake in Trillium Therapeutics in the fourth quarter worth about $35,000. Jane Street Group LLC purchased a new stake in Trillium Therapeutics in the fourth quarter worth about $43,000. Geode Capital Management LLC increased its position in Trillium Therapeutics by 164.0% in the fourth quarter. Geode Capital Management LLC now owns 26,627 shares of the biotechnology company’s stock worth $45,000 after buying an additional 16,541 shares in the last quarter. Finally, Morgan Stanley increased its position in Trillium Therapeutics by 25.2% in the third quarter. Morgan Stanley now owns 356,655 shares of the biotechnology company’s stock worth $2,068,000 after buying an additional 71,860 shares in the last quarter. Institutional investors and hedge funds own 39.43% of the company’s stock.

Trillium Therapeutics Company Profile

Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trials for advanced hematologic malignancies, and solid tumors and mycosis fungoides.

See Also: Economic Reports

Get a free copy of the Zacks research report on Trillium Therapeutics (TRIL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.